Article Sidebar
Article Details
Issue
Section
Articles
Copyright of articles published shall reside exclusively with the Faculty of Pharmaceutical Sciences, University of Jos.
DECLARATION & COPYRIGHT TRANSFER
I/We the undersigned author(s) of article entitled
…………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………
Declare as follows:
- The manuscript submitted to Journal of Pharmacy & Bioresources is original and has not been and will be published, whole or in part, in print or electronic format, in any other journal. It is also not being currently considered for publication in any journal.
- The submitted manuscript is a joint decision of all the coauthors.
- Each author has participated sufficiently in the work to warrant his or her inclusion in the list of authors. To this end, each author takes responsibility for appropriate portions of the manuscript.
- Authors have obtained necessary approval to carry out the experiments on animals and human subjects. Approval certificates will be furnished, if required by publishers or editors of the journal.
- Authors do not have any conflict of interest (financial or otherwise) other than those declared.
- If the manuscript is accepted for publication, the authors transfer and assign copyright of the article referenced above to Journal of Pharmacy and Bioresources.
Name & Signature of authors
1. 2.
- 4.
- 6.
- 8.
Corresponding authors name address, affiliation and email:
Main Article Content
Efficacy of single-dose amodiaquine co-administered with sulfadoxine/pyrimethamine against falciparum infection in Barkin Ladi, an area of multi-drug resistant malaria
Abstract
A study was conducted in Barkin Ladi on the North Central plateau of Nigeria to assess the efficacy and tolerability of a single-dose (10 mg/kg) amodiaquine co-administered with sulfadoxine/pyrimethamine (SP) against Plasmodium falciparum malaria in children less than 5 years of age using a 14-day protocol. The combination was highly efficacious in 41 patients involved in the trial, producing rapid parasite clearance (MPCR= 2.73 days) and faster clearance of fever (MFCR= 1.2 days). Adequate clinical and parasitological response (ACPR) achieved was 97.6%, while there was 1 (2.4%) case of late parasitological failure (LPF). The single-dose combination produced a significant improvement in PCV (p<0.05; t= 6.390, df = 37), from an average value of 28.7% (±5.2%) on D0 to 34.2% (±3.4%) on D14. The drug combination was well tolerated by the patients; only 2 (4.8%) cases of pruritus occurred amongst the children. The results confirm the efficacy of SP-amodiaquine combination therapy against falciparum malaria.
Keywords: Amodiaquine; Sulfadoxine/Pyrimethamine; Malaria; Nigeria
Journal of Pharmacy and Bioresources Vol. 3 (1) 2006: pp. 1-6
